Celgene reports positive Revlimid phase III trial data

Celgene has reported positive clinical data from three phase III studies of Revlimid (lenalidomide), its therapy for multiple myeloma.

The drug has been trialled in a continuous treatment regimen among patients with newly-diagnosed multiple myeloma and as a maintenance treatment following autologous stem cell transplant.

In the first of the three trials, Revlimid was shown to offer superior performance to a placebo-based regimen among newly-diagnosed elderly patients, while the remaining two provided similarly positive results among more than 1,000 transplant patients.

The manufacturer said: "All three publications highlight the expanding body of clinical evidence supporting lenalidomide treatment in these areas."

To date, Revlimid has been approved in nearly 70 countries across Europe, the Americas, the Middle East and Asia, with applications being considered in a number of other regions.

Last month, Celgene reported its financial results for the first quarter of 2012, during which the company experienced year-on-year sales growth of 17 percent.